Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Masayuki Iyoda"'
Autor:
Nobuhiro Kanazawa, Masayuki Iyoda, Taihei Suzuki, Shohei Tachibana, Ryuichi Nagashima, Hirokazu Honda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Minimal change disease (MCD), a common cause of idiopathic nephrotic syndrome, has been postulated to exhibit an association with allergic conditions. Recent studies revealed the crucial role of interleukin (IL)-33 in type 2 innate immunity.
Externí odkaz:
https://doaj.org/article/6e2a60698ce84e67b1cc7651bde235b4
Autor:
Chikara Kohda, Satoshi Ino, Hiroki Ishikawa, Yoshihiro Kuno, Ryuichi Nagashima, Masayuki Iyoda
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 5 (2023)
ABSTRACT Human cytomegalovirus (HCMV) is a member of Herpesviridae. It has been reported that HCMV is reactivated in the breast milk of HCMV-seropositive lactating women. As we have reported various aspects of the roles of indigenous microbiota, its
Externí odkaz:
https://doaj.org/article/09db64fb845c403bb0168dbd1800fd87
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitors are therapeutic agents for renal anemia that work through HIF2-mediated upregulation of erythropoietin (EPO) and have also been reported to suppress renal fibrosis. Group 2 inn
Externí odkaz:
https://doaj.org/article/664a47abb5be49738020ad4af95f8038
Autor:
Nobuhiro Kanazawa, Masayuki Iyoda, Taihei Suzuki, Shohei Tachibana, Ryuichi Nagashima, Hirokazu Honda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/ce88c793a011452fb0e0b8b882176f6f
Autor:
Nobuhiro Kanazawa, Masayuki Iyoda, Shohei Tachibana, Kei Matsumoto, Yukihiro Wada, Taihei Suzuki, Ken Iseri, Takanori Shibata
Publikováno v:
Kidney & Blood Pressure Research, Pp 1-16 (2020)
Background: Recombinant human soluble thrombomodulin (rhTM) was approved in 2008 and has been used for treatment of disseminated intravascular coagulation in Japan. The antifibrotic effects of rhTM in acute exacerbation of idiopathic pulmonary fibros
Externí odkaz:
https://doaj.org/article/8640c33d1e8844219e09d634fd5ae110
Autor:
Ryuichi Nagashima, Masayuki Iyoda
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Innate lymphoid cells (ILCs) are a recently discovered lymphocyte population with high cytokine productive capacity. Type-2 ILCs (ILC2s) are the most studied, and they exert a rapid type-2 immune response to eliminate helminth infections. Massive and
Externí odkaz:
https://doaj.org/article/3e6115ddcc164e908d9e9c610ebb62f6
Autor:
Yukihiro Wada, Masayuki Iyoda, Kei Matsumoto, Taihei Suzuki, Shohei Tachibana, Nobuhiro Kanazawa, Hirokazu Honda
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245340 (2021)
IntroductionInterleukin-34 (IL-34) shares a receptor (cFMS) with colony stimulating factor-1 (CSF-1), and these two ligands mediate macrophage proliferation. However, in contrast to CSF-1, the influence of IL-34 on tubular epithelial cells (TECs) inj
Externí odkaz:
https://doaj.org/article/2bd76173b3a34598aa053699551a04ee
Autor:
Motonori Sugiyama, Yukihiro Wada, Nobuhiro Kanazawa, Shohei Tachibana, Taihei Suzuki, Kei Matsumoto, Masayuki Iyoda, Hirokazu Honda, Takanori Shibata
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0232194 (2020)
IntroductionRecent studies noted that Henoch-Schönlein purpura nephritis (HSPN) and IgA nephropathy (IgAN) share the feature of galactose-deficient IgA1 (Gd-IgA1)-oriented pathogenesis, although there are distinct clinical differences. We aimed to c
Externí odkaz:
https://doaj.org/article/b004f760810748db870ceeec2a840199
Autor:
Shohei Tachibana, Masayuki Iyoda, Taihei Suzuki, Nobuhiro Kanazawa, Ken Iseri, Yukihiro Wada, Kei Matsumoto, Takanori Shibata
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0224690 (2019)
BACKGROUND:Uromodulin (UMOD), also known as Tamm-Horsfall protein, is a kidney-specific protein expressed by epithelial cells lining the thick ascending limb of the loop of Henle. In the current study, we aimed to clarify the clinical significance of
Externí odkaz:
https://doaj.org/article/6f18b316478f4ad9935542aaf6c206d7
Autor:
Ken Iseri, Masayuki Iyoda, Makoto Watanabe, Kei Matsumoto, Daisuke Sanada, Takashi Inoue, Shohei Tachibana, Takanori Shibata
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0193846 (2018)
The clinical utility of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) has yet to be established. This study aimed to compare the effects of denosumab on bone mineral density (BMD) and bone turnover markers to those of alen
Externí odkaz:
https://doaj.org/article/2ccc1405f2344bcfad175a9e18bfd080